Poor health literacy in nulliparous women who are engaged in early prenatal care often leads to adverse maternal and neonatal outcomes, according to a study, adding that this must be considered a social determinant of perinatal health.
The timing of betamethasone (BMZ) administration in pregnant women does not seem to differentially affect the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and, in turn, has no apparent effect on neonatal outcomes, according to a study presented at recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).
Pregnant women may do well to exercise at an adequate amount, as it lowers the likelihood of adverse obstetric outcomes independent of blood pressure, according to a study presented at the Society for Maternal-Fetal Medicine (SMFM) 40th Annual Pregnancy Meeting.
In women undergoing intrauterine insemination after ovarian stimulation (OS-IUI) for the treatment of unexplained infertility, the use of gonadotropin vs other oral medications carries an increased risk of multiple gestation for every birth gained, as reported in a recent study.
The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).
Being of type O blood may increase the risk of postpartum haemorrhage (PPH) during caesarean delivery, according to a new study presented at the recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.